Trends in Retinal Detachment Repairs per UC Davis Eye Center Study | ASRS 2024

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial comparing it with Eylea 2 mg is under way.

Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea HD in patients with neovascular (wet) age-related macular degeneration.

IRX-101, a new antiseptic tested in patients receiving eye injections for macular degeneration, resulted in less pain and fewer adverse events than povidone-iodine.

Small doses of the involuntary nervous system blocker, atropine, may offer a non-invasive treatment for symptomatic vitreous floaters, according to a recent small study.

Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be required to treat patients with advanced disease or complex cases.